2013 American Transplant Congress
Improved Bioavailability of MELTDOSE Once-Daily Formulation of Tacrolimus (LCP-Tacro) with Controlled Agglomeration Allows for Consistent Absorption over 24 Hrs: A Scintigraphic and Pharmacokinetic Evaluation
Veloxis Pharmaceuticals, Edison, NJ
MeltDose® is a process technology intended to enhance oral bioavailability of poorly water soluble compounds. We evaluated the transit time, pharmacokinetic (PK) profile and site…2013 American Transplant Congress
Characterization of Human CD8+/TCR-/CD56dim/- Facilitating Cells In Vivo and In Vitro
We previously reported that bone marrow-derived CD8+/TCR- graft facilitating cells (FC) significantly enhance engraftment of HSC and prevent GVHD in mouse recipients. We have presently…2013 American Transplant Congress
Pre-Recovery Liver Biopsy in Brain Death Donors – Case Control Study of Safety, Feasibility and Liver Utilization
Department of Surgery, UMDNJ-NJMS, Newark, NJ
Background: Pre-recovery liver biopsy (PLB) has potential to decrease costs of futile liver recovery and increase recovered utilization, therefore we examined its safety, feasibility, and…2013 American Transplant Congress
Anti-TIM-4 Mediates Long-Term Engraftment of Islet Allografts by Promoting IL-10 Expression by TIM-1+ Bregs and Inhibiting IFNγ Expression by Proinflammatory “Be1” B Cells
University of Pittsburgh, Pittsburgh; Harvard Medical School, Boston
We recently defined TIM-1 as an inclusive marker for IL-10 expressing regulatory B cells (Bregs). Moreover, Α-TIM-1 mAb prolongs allograft survival (GS) through induction of…2013 American Transplant Congress
Monotherapy with HuABC2, a Novel Humanized Antibody Against CD122 (The IL-2/IL-15 Receptor β Chain), Prolongs the Survival Times of Non-Human Primate (NHP) Recipients of Life-Sustaining Renal Allografts
Background: CD122 is the Β chain of the receptors for IL-2 and IL-15, two key cytokines implicated in transplant rejection. HuABC2 (humanized IgG1, kappa) is…2013 American Transplant Congress
Delayed HCC MELD Exception Score Improves Disparity in Access to Liver Transplant
Background: In the US, wait-list dropout is lower and the transplant rate higher for candidates with standard MELD exception for hepatocellular carcinoma (HCC) than for…2013 American Transplant Congress
Choice of Induction Therapy in Kidney Transplant: It’s Race Not PRA
Background: rATG and IL-2RA are the most common induction agents used for KTX. There is no consensus on choice of induction. The aim of this…2013 American Transplant Congress
Genetic Adaptation of Polyomavirus BK (BKV) to Immunologic and Pharmacologic Selection Pressure
BACKGROUND: Characterizing the genomic plasticity of BKV will further our understanding of viral epidemiology, diagnosis, and clinical outcome, and facilitate development of vaccines and drug…2013 American Transplant Congress
FL/G-CSF/AMD3100 Mobilized Hematopoietic Stem Cells Induce Mixed Chimerism with Nonmyeloablative Conditioning and Transplantation Tolerance without GVHD
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
Mobilized hematopoietic stem cells (HSC) now serve as a major source for transplantation. Better mobilizing approaches are clinically important. AMD3100, a CXCR4 competitive inhibitor, has…2013 American Transplant Congress
Experience with Linezolid (LZD) for the Treatment of Nocardiosis in Solid Organ Transplant Recipients (SOT)
University of Pittsburgh Medical Center, Pittsburgh; Affiliated Community Medical Centers, Willmar
Objectives: Combination therapy including amikacin is recommended for the treatment of severe Nocardia infections. Use of amikacin in SOT is difficult due to renal dysfunction…
- « Previous Page
- 1
- …
- 149
- 150
- 151
- 152
- 153
- …
- 178
- Next Page »